Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Import Safety Agreement Further Entwines FDA/China Regulatory Process

This article was originally published in PharmAsia News

Executive Summary

Chinese manufacturers of certain drugs or active pharmaceutical ingredients selected by FDA will have to meet new registration standards as part of a memorandum of understanding signed Dec. 11 in Beijing by HHS, FDA and China's State Food and Drug Administration
Advertisement

Related Content

U.S. FDA Commissioner Hamburg Promotes Regulatory Science Collaboration In China Visit
Asia Spotlight: U.S. Congressmen Call On FDA Commissioner To Press Investigation Into Adulterated Heparin During Upcoming Trip To China
U.S. Congressmen Call On FDA Commissioner To Press Investigation Into Adulterated Heparin During Upcoming Trip To China
China Prepares To Send Food And Drug Safety Officials To The U.S.
U.S. FDA Set To Strengthen Inspections Of Chinese Drugmakers, Search For Adulterants In Aftermath Of Heparin Deaths – CDER Official
Vietnam, U.S. Sign Import Agreement On Medical Products
Chinese Contaminant Was Inexpensive Heparin Mimic – U.S. FDA
NPA, USP Provide GMP Support To Chinese Dietary Supplement Suppliers
U.S. FDA Eyes Five Global Regions For Permanent Outposts
Sidley Austin Beijing Senior Counsel Chen Yang: An Interview with PharmAsia News
Advertisement
UsernamePublicRestriction

Register

SC065887

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel